Molecular NeurodegenerationNeurosciencePeer-reviewed journal article
Diabetic phenotype in mouse and humans with β-amyloid pathology reduces the number of microglia around β-amyloid plaques
Teemu NatuneniD, Henna MartiskaineniD, Mikael MarttineniD, Sami GabboujiD, Hennariikka Koivisto, Susanna KemppaineniD, Satu Kaipainen, Mari TakaloiD, Helena SvobodováiD, Luukas Leppänen, Benjam KemiläineniD, Simo Ryhänen, Teemu KuulasmaaiD, Eija RahuneniD, Sisko Juutinen, Petra M. Mäkinen, Pasi Miettinen, Tuomas H. RauramaaiD, Jussi PihlajamäkiiD, Annakaisa HaapasaloiD, Ville LeinoneniD, Heikki TanilaiD, Mikko HiltuneniD
Abstract
Type 2 diabetes (T2D) increases the risk of Alzheimers disease (AD). Even though these two diseases share common molecular pathways, the mechanisms remain elusive. To shed light into these mechanisms, mice with different AD- and/or tauopathy-linked genetic backgrounds were utilized; APPswe/PS1dE9 (A+Tw), Tau P301L (AwT+), and APPswe/PS1dE9/Tau P301L (A+T+). Feeding these mice with typical Western diet (TWD) led to obesity and diabetic phenotype as compared to respective mice with a standard diet. TWD also exacerbated memory and learning impairment in A+Tw and AwT+, but not in A+T+ mice. Furthermore, RNA sequencing of mouse hippocampal samples revealed altered responses to AD-related pathologies in A+Tw and A+T+ mice upon TWD, pointing specifically towards aberrant microglial functionality and PI3K-Akt signaling. Accordingly, fewer microglia alongside an increased number of dystrophic neurites around {beta}-amyloid plaques, and impaired PI3K-Akt signaling, were discovered in the hippocampus of TWD mice. Mechanistic elucidation revealed that disruption of the PI3K-Akt signaling pathway by pharmacological or genetic approaches significantly decreased the phagocytic uptake and proinflammatory response as well as increased the activity of Syk-kinase upon ligand-induced activation of Trem2/Dap12 signaling in mouse microglia. Finally, characterization of microglial pathology in cortical biopsies of idiopathic normal pressure hydrocephalus (iNPH) patients harboring {beta}-amyloid plaques revealed a significant decrease in the number of microglia per {beta}-amyloid plaque in obese iNPH patients with T2D as compared to both normal weight and obese iNPH patients without T2D. Collectively, these results suggest that the peripheral diabetic phenotype in mice and humans associates with reduced microglial response to {beta}-amyloid pathology.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: cell-cell communication
- approach: statistical model
- Citations
- 35
- FWCI
- 2.41
- Field percentile
- top 10%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Aβ and Neuroinflammatory Response Exacerbating Alzheimer-like Neuropathology
Wenqiang Chen, Xiangyu Liu, … C. Ronald Kahn·bioRxiv·Aug 22, 2024
- PTP1B inhibition promotes microglial phagocytosis in Alzheimer's disease models by enhancing SYK signaling
Yuxin Cen, Steven R. Alves, … Nicholas K. Tonks·Proceedings of the National Academy of SciencesPeer-reviewed·Feb 2, 2026
- DIET INFLUENCES PERIPHERAL AMYLOID BETA METABOLISM: A ROLE FOR CIRCULATING INSULIN-LIKE GROWTH FACTOR I
Raquel Herrero-Labrador, Ángel Trueba-Sáiz, … I. Torres Aleman·bioRxiv·Jul 9, 2020
- The mechanism and consequences of amyloid-β modulating thiamine pyrophosphokinase-1 expression in microglia
Xiaoqin Cheng, Ruoqi Zhao, … Chunjiu Zhong·bioRxiv·Sep 18, 2024
- Fibrillar Aβ causes profound microglial metabolic perturbations in a novel APP knock-in mouse model
Dan Xia, Steve Lianoglou, … Pascal E. Sanchez·bioRxiv·Jan 19, 2021
- Effects of rising amyloidβ levels on hippocampal synaptic transmission, microglial response and cognition in APPSwe/PSEN1M146V transgenic mice
Evelyn Medawar, Tiffanie A. Benway, … Frances A. Edwards·EBioMedicinePeer-reviewed·Dec 13, 2018